HCC
MCID: HPT023
MIFTS: 98

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 57 38 12 76 59 75 37 29 13 55 6 15
Liver Cancer 57 12 75 43 15
Hepatoma 57 12 75 15
Hcc 57 12 59 75
Primary Liver Cancer 12 53 15
Adult Primary Hepatocellular Carcinoma 12 73
Primary Malignant Neoplasm of Liver 12 73
Malignant Neoplasm of Liver 12 73
Hepatoblastoma, Somatic 57 13
Cancer, Hepatocellular 57 40
Neoplasm of the Liver 29 6
Liver Cell Carcinoma 57 75
Liver Neoplasms 44 73
Hepatic Cancer 12 55
Hepatoblastoma 59 73
Liver Neoplasm 12 15
Lcc 57 75
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 53
Hepatocellular Carcinoma, Childhood Type, Somatic 57
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 73
Resectable Malignant Neoplasm of the Liver 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 57
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 53
Malignant Hepatobiliary Neoplasm 73
Hepatocellular Cancer, Somatic 57
Primary Tumor of the Liver 53
Liver Cell Carcinoma; Lcc 57
Carcinoma, Hepatocellular 44
Malignant Tumor of Liver 12
Primary Cancer of Liver 53
Primary Liver Carcinoma 53
Hepatocellular Cancer 75
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 73
Adult Hepatoma 12

Characteristics:

Orphanet epidemiological data:

59
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

32
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to childhood hepatocellular carcinoma and adult hepatocellular carcinoma, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Feridex I.V. and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and endothelial, and related phenotypes are hypotension and hepatomegaly

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

OMIM : 57 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

UniProtKB/Swiss-Prot : 75 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 76 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 789)
# Related Disease Score Top Affiliating Genes
1 childhood hepatocellular carcinoma 34.7 CTNNB1 MET
2 adult hepatocellular carcinoma 34.6 TP53 PIK3CA PDGFRL CTNNB1 CASP8 AXIN1
3 cholangiocarcinoma 32.6 TP53 TERT PIK3CA MIR21 MET KRAS
4 intrahepatic cholangiocarcinoma 32.0 TP53 KRAS IDH2 IDH1 CTNNB1
5 adenocarcinoma 31.9 TP53 PIK3CA KRAS HRAS FGFR1 CTNNB1
6 colorectal cancer 31.7 TP53 TERT PIK3CA PDGFRL NRAS NFE2L2
7 adenoma 31.6 APC CTNNB1 KRAS TP53
8 breast cancer 31.6 TP53 TERT PIK3CA MIR21 MIR122 MET
9 gastric cancer 31.4 TP53 TERT PIK3CA MIR21 MIR122 MET
10 hepatoblastoma 31.4 APC CTNNB1 TP53
11 neuroblastoma 31.4 AKT1 CASP8 CTNNB1 FGFR1 NRAS PIK3CA
12 squamous cell carcinoma 31.3 AKT1 CTNNB1 HRAS PIK3CA TP53
13 lung cancer susceptibility 3 31.3 TP53 TERT PIK3CA NRAS NFE2L2 MET
14 lung cancer 31.3 AKT1 CASP8 FGFR1 HRAS KRAS MET
15 esophageal cancer 31.2 TP53 TERT PIK3CA MIR21 KRAS HRAS
16 gastric adenocarcinoma 31.2 TP53 PIK3CA NRAS MET KRAS HRAS
17 prostate cancer 31.1 TP53 TERT PIK3CA MIR21 MET KRAS
18 glioma 31.1 TP53 PIK3CA MIR21 MET IDH2 IDH1
19 pancreatic cancer 31.1 AKT1 CTNNB1 HRAS KRAS MET MIR21
20 glioblastoma 31.1 TP53 PIK3CA NRAS MIR21 MET IDH2
21 cervical cancer 31.0 TP53 TERT PIK3CA NFE2L2 MIR21 HRAS
22 familial adenomatous polyposis 31.0 APC AXIN1 CTNNB1 KRAS TP53
23 myeloma, multiple 30.9 TP53 NRAS KRAS IDH2 IDH1 HRAS
24 sarcoma 30.9 CTNNB1 HRAS KRAS PIK3CA TP53
25 pancreas adenocarcinoma 30.9 MET KRAS HRAS CTNNB1 AKT1 TP53
26 adrenocortical carcinoma, hereditary 30.9 CTNNB1 NRAS PIK3CA TP53
27 gallbladder cancer 30.9 AKT1 KRAS PIK3CA TERT TP53
28 ovarian cancer 30.9 AKT1 CASP8 CTNNB1 KRAS MIR21 PIK3CA
29 colon adenocarcinoma 30.8 APC CASP8 CTNNB1 KRAS
30 liver angiosarcoma 30.7 HRAS KRAS NRAS TP53
31 nasopharyngeal carcinoma 30.7 TP53 TERT PIK3CA NRAS HRAS CTNNB1
32 adamantinoma of long bones 30.7 TP53 TERT PIK3CA KRAS CTNNB1 CASP8
33 small cell cancer of the lung 30.7 AKT1 MIR21 PIK3CA TP53
34 adenosquamous carcinoma 30.6 KRAS PIK3CA TP53
35 lymphoma, non-hodgkin, familial 30.6 CASP8 NRAS PIK3CA TP53
36 gastrointestinal system disease 30.6 AKT1 CTNNB1 HRAS KRAS TP53
37 carcinosarcoma 30.6 TP53 PIK3CA KRAS HRAS CTNNB1
38 breast adenocarcinoma 30.5 AKT1 CASP8 KRAS PIK3CA TP53
39 bladder cancer 30.5 HRAS KRAS MIR21 TERT TP53
40 cystadenocarcinoma 30.5 AKT1 HRAS PIK3CA TP53
41 myeloid leukemia 30.5 HRAS IDH1 NRAS TP53
42 ovary adenocarcinoma 30.5 HRAS KRAS PIK3CA TP53
43 colorectal adenocarcinoma 30.5 CTNNB1 HRAS KRAS TP53
44 tongue squamous cell carcinoma 30.4 AKT1 CTNNB1 MIR21 TP53
45 lynch syndrome 30.4 APC CTNNB1 KRAS TP53
46 kidney cancer 30.4 MET MIR122 MIR21 TP53
47 embryonal sarcoma 30.4 AXIN1 CTNNB1 TP53
48 glioblastoma multiforme 30.4 AKT1 IDH1 MET MIR21 PIK3CA TP53
49 biliary tract neoplasm 30.4 HRAS KRAS TP53
50 cowden disease 30.3 AKT1 MIR21 PIK3CA

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Symptoms via clinical synopsis from OMIM:

57
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer


Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

59 32 (show all 50)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 59 32 very rare (1%) Very rare (<4-1%) HP:0002615
2 hepatomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0002240
3 type ii diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0005978
4 portal hypertension 59 32 hallmark (90%) Very frequent (99-80%) HP:0001409
5 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
6 hypokalemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002900
7 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
8 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
9 hypoglycemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001943
10 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
11 anemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001903
12 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
13 neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0002664
14 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
15 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
16 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
17 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
18 thrombocytosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001894
19 hyponatremia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002902
20 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
21 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
22 bone pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002653
23 internal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0011029
24 esophageal varix 59 32 frequent (33%) Frequent (79-30%) HP:0002040
25 venous insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0005293
26 liver abscess 59 32 very rare (1%) Very rare (<4-1%) HP:0100523
27 hyperbilirubinemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002904
28 abdominal distention 59 32 frequent (33%) Frequent (79-30%) HP:0003270
29 polycythemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001901
30 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741
31 hypoalbuminemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003073
32 poor appetite 59 32 occasional (7.5%) Occasional (29-5%) HP:0004396
33 abnormality of the rectum 59 32 frequent (33%) Frequent (79-30%) HP:0002034
34 metabolic alkalosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0200114
35 mood changes 59 32 occasional (7.5%) Occasional (29-5%) HP:0001575
36 hepatic encephalopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002480
37 abnormality of glycoprotein metabolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0004367
38 budd-chiari syndrome 59 32 very rare (1%) Very rare (<4-1%) HP:0002639
39 hepatic necrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002605
40 epigastric pain 59 32 frequent (33%) Frequent (79-30%) HP:0410019
41 anasarca 59 32 occasional (7.5%) Occasional (29-5%) HP:0012050
42 hemobilia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100762
43 elevated hepatic transaminases 59 Frequent (79-30%)
44 abnormality of the liver 59 Very frequent (99-80%)
45 hepatocellular carcinoma 32 HP:0001402
46 constitutional symptom 59 Occasional (29-5%)
47 abnormality of the hepatic vasculature 59 Very frequent (99-80%)
48 micronodular cirrhosis 32 HP:0001413
49 subacute progressive viral hepatitis 32 HP:0006572
50 elevated hepatic transaminase 32 frequent (33%) HP:0002910

UMLS symptoms related to Hepatocellular Carcinoma:


nausea and vomiting, constipation, fever, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.6 KRAS
3 Decreased viability GR00221-A-1 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA NRAS
4 Decreased viability GR00221-A-2 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.6 AKT1 HRAS NRAS
6 Decreased viability GR00221-A-4 10.6 AKT1 PIK3CA
7 Decreased viability GR00301-A 10.6 KRAS
8 Decreased viability GR00381-A-1 10.6 KRAS
9 Decreased viability GR00402-S-2 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA NRAS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.27 IGF2R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.27 IGF2R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.27 CTNNB1 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.27 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.27 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.27 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.27 IGF2R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.27 PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.27 PIK3CA AKT1 IDH2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.27 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.27 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.27 IDH2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.27 APC CTNNB1 KRAS PIK3CA AKT1 IDH2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.27 PIK3CA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.27 APC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.27 KRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.27 CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.27 IDH2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.27 APC
29 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.27 IGF2R
30 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.27 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.27 IGF2R
32 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.27 APC
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.27 PIK3CA AKT1 IDH2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.27 CTNNB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.27 APC CTNNB1 IGF2R KRAS PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.27 KRAS AKT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.27 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.27 CTNNB1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.27 IDH2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.27 AKT1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.27 CTNNB1 IGF2R IDH2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.27 APC CTNNB1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.27 CTNNB1 AKT1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.27 AKT1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.27 KRAS
46 Decreased cell migration GR00055-A-1 9.73 AKT1 CTNNB1 HRAS KRAS MET PIK3CA
47 Increased cell migration GR00055-A-3 9.26 CTNNB1 HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
2 growth/size/body region MP:0005378 10.49 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
3 cellular MP:0005384 10.47 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
4 behavior/neurological MP:0005386 10.45 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
5 homeostasis/metabolism MP:0005376 10.44 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
6 embryo MP:0005380 10.42 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
7 endocrine/exocrine gland MP:0005379 10.41 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
8 mortality/aging MP:0010768 10.41 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
9 immune system MP:0005387 10.37 AKT1 APC CASP8 CTNNB1 FGFR1 IDH1
10 craniofacial MP:0005382 10.36 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
11 digestive/alimentary MP:0005381 10.35 APC AXIN1 CTNNB1 FGFR1 HRAS KRAS
12 hematopoietic system MP:0005397 10.35 AKT1 APC CASP8 CTNNB1 FGFR1 IDH1
13 nervous system MP:0003631 10.3 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
14 integument MP:0010771 10.29 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
15 neoplasm MP:0002006 10.29 AKT1 APC CASP8 CTNNB1 HRAS IDH2
16 liver/biliary system MP:0005370 10.22 AKT1 APC CASP8 CTNNB1 IGF2R KRAS
17 normal MP:0002873 10.22 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
18 limbs/digits/tail MP:0005371 10.19 APC AXIN1 CTNNB1 FGFR1 IGF2R KRAS
19 muscle MP:0005369 10.15 AKT1 APC CASP8 CTNNB1 FGFR1 KRAS
20 no phenotypic analysis MP:0003012 10.09 APC CTNNB1 FGFR1 HRAS KRAS MET
21 hearing/vestibular/ear MP:0005377 10.06 APC AXIN1 CTNNB1 FGFR1 KRAS TP53
22 renal/urinary system MP:0005367 10.06 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
23 reproductive system MP:0005389 9.96 AKT1 APC AXIN1 CTNNB1 FGFR1 IGF2R
24 respiratory system MP:0005388 9.93 AKT1 AXIN1 CASP8 CTNNB1 HRAS IDH1
25 skeleton MP:0005390 9.8 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
26 pigmentation MP:0001186 9.77 APC CTNNB1 KRAS NRAS TP53
27 vision/eye MP:0005391 9.23 APC CTNNB1 FGFR1 KRAS MET NRAS

Drugs & Therapeutics for Hepatocellular Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Feridex I.V. 18 FERUMOXIDES Advanced Magnetics February 1996
2
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-92-0 936
2
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
3
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 198153-51-4 5360545
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 36791-04-5 37542
5
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 134678-17-4 60825
6
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
8
Carboplatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 41575-94-4 10339178 38904 498142
9
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
10
Cefazolin Approved Phase 4 25953-19-9 656510 33255
11
acetic acid Approved Phase 4 64-19-7 176
12
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 525-66-6 4946
13
Telbivudine Approved, Investigational Phase 4,Phase 1,Phase 2 3424-98-4 159269
14
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
15
Coal tar Approved Phase 4,Phase 3,Phase 2 8007-45-2
16
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7553-56-2 807
17
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
18
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
19
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Nadolol Approved Phase 4 42200-33-9 39147
22
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
23
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
24
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
25
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
26
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
27
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
29
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
32
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
33
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
34
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
35
Norepinephrine Approved Phase 4 51-41-2 439260
36
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
37
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Not Applicable 1190307-88-0 45375808
38
Ledipasvir Approved Phase 4,Phase 3 1256388-51-8 67505836
39
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3 24280-93-1 446541
40
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
41
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
42
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
43
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
44
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
45
Warfarin Approved Phase 4,Not Applicable 81-81-2 6691 54678486
46
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6 772 46507594
47
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
48
Dipyridamole Approved Phase 4 58-32-2 3108
49
Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
50
Dalteparin Approved Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6

Interventional clinical trials:

(show top 50) (show all 1941)
# Name Status NCT ID Phase Drugs
1 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
2 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
3 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
4 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
5 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
6 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
7 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
8 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
9 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
10 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
11 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
12 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
13 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
14 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
15 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
16 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
17 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
18 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
19 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
20 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
21 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
22 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
23 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
24 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
25 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
26 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
27 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
28 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
29 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
30 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
31 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
32 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
33 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
34 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
35 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy Recruiting NCT02399033 Phase 4 Xihuang Capsules
36 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
37 Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting NCT02525380 Phase 4
38 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
39 Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria Recruiting NCT02138981 Phase 4
40 Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma Not yet recruiting NCT03515369 Phase 4 Babaodan oral capsule;Placebo oral capsule
41 Drug-eluting Bead in Hepatocellular Carcinoma Completed NCT01332669 Phase 4
42 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
43 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Terminated NCT01600196 Phase 4
44 Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT01409499 Phase 4 sorafenib
45 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
46 Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). Completed NCT01798160 Phase 4
47 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4 Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
48 Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma Completed NCT00829465 Phase 4 Licartin
49 TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma Recruiting NCT02435953 Phase 4
50 Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: carcinoma, hepatocellular

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53
2 Neoplasm of the Liver 29

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

41
Liver, T Cells, Endothelial, Lung, Testes, Breast, Bone

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 15755)
# Title Authors Year
1
Mortality from liver angiosarcoma, hepatocellular carcinoma, and cirrhosis among vinyl chloride workers. ( 30474170 )
2019
2
Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. ( 30536104 )
2019
3
T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. ( 30518547 )
2019
4
No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. ( 30142097 )
2019
5
Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. ( 30199473 )
2019
6
lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression. ( 30546959 )
2019
7
LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. ( 30551364 )
2019
8
Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation. ( 30551417 )
2019
9
Chemopreventive mechanisms of galangin against hepatocellular carcinoma: A review. ( 30551461 )
2019
10
Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo. ( 30551496 )
2019
11
Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation. ( 30551534 )
2019
12
miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT. ( 30551553 )
2019
13
MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3. ( 30554487 )
2019
14
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. ( 30510994 )
2019
15
Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma. ( 30527495 )
2019
16
Role of microRNAs in the development of hepatocellular carcinoma and drug resistance. ( 30468662 )
2019
17
Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance. ( 30468672 )
2019
18
RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. ( 30496760 )
2019
19
Hepatocellular carcinoma in Gaucher disease: Reinforcing the proposed guidelines. ( 30446378 )
2019
20
Hypoxia induced δ-Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling. ( 30458179 )
2019
21
COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway. ( 30365092 )
2019
22
Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. ( 30389456 )
2019
23
Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. ( 30321589 )
2019
24
CircRNA has_circ_0078710 acts as the sponge of microRNA-31 involved in hepatocellular carcinoma progression. ( 30342168 )
2019
25
Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma. ( 30292871 )
2019
26
MicroRNA-645 represses hepatocellular carcinoma progression by inhibiting SOX30-mediated p53 transcriptional activation. ( 30312695 )
2019
27
The competing endogenous circular RNA ADAMTS14 suppressed hepatocellular carcinoma progression through regulating microRNA-572/regulator of calcineurin 1. ( 30317540 )
2019
28
Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. ( 30256409 )
2019
29
Cytotoxicity of Luffa cylindrica (L.) M.Roem. extract against circulating cancer stem cells in hepatocellular carcinoma. ( 30287196 )
2019
30
HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. ( 30523627 )
2019
31
4-Acetylantroquinonol B from antrodia cinnamomea enhances immune function of dendritic cells against liver cancer stem cells. ( 30551483 )
2019
32
Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer. ( 30151798 )
2019
33
miR-365 regulates liver cancer stem cells via RAC1 pathway. ( 30182377 )
2019
34
A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer. ( 30191950 )
2019
35
Catalytic hairpin assembly-programmed formation of clickable nucleic acids for electrochemical detection of liver cancer related short gene. ( 30454575 )
2019
36
Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling. ( 30248355 )
2019
37
The prognostic value of Niemann-Pick C1-like protein 1 and Niemann-Pick disease type C2 in hepatocellular carcinoma. ( 29483961 )
2018
38
CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression. ( 28360097 )
2018
39
Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. ( 29127494 )
2018
40
Rottlerin upregulates DDX3 expression in hepatocellular carcinoma. ( 29203243 )
2018
41
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension. ( 29970660 )
2018
42
<i>Tachypleus tridentatus</i> Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. ( 29880736 )
2018
43
Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-I+ derived from adipocyte. ( 29976395 )
2018
44
Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. ( 29277614 )
2018
45
Glutamine synthetase mediates sorafenib sensitivity in I^-catenin-active hepatocellular carcinoma cells. ( 29303508 )
2018
46
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. ( 29034998 )
2018
47
miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. ( 29360449 )
2018
48
Tetrandrine Enhances Radiosensitization in Human Hepatocellular Carcinoma Cell Lines. ( 29979637 )
2018
49
Efficacy of<sup>125</sup>I Versus Non-<sup>125</sup>I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )
2018
50
A human-specific switch of alternatively spliced<i>AFMID</i>isoforms contributes to<i>TP53</i>mutations and tumor recurrence in hepatocellular carcinoma. ( 29449409 )
2018